{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:23:14Z","timestamp":1777515794305,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jocn.2021.09.035","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T17:37:13Z","timestamp":1632764233000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clinical characteristics, disease course, and outcomes of paediatric patients with myelin oligodendrocyte glycoprotein-Ab associated disease: A retrospective clinical study"],"prefix":"10.1016","volume":"94","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuizhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2021.09.035_b0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflam"},{"issue":"5","key":"10.1016\/j.jocn.2021.09.035_b0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"21","key":"10.1016\/j.jocn.2021.09.035_b0015","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"OFSEP and NOMADMUS Study Group. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jocn.2021.09.035_b0020","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Maciej","year":"2017","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.jocn.2021.09.035_b0025","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG\u2013associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.jocn.2021.09.035_b0030","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2021.09.035_b0035","doi-asserted-by":"crossref","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al., Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2017; 89(2):127-137.","DOI":"10.1136\/jnnp-2017-316880"},{"issue":"5","key":"10.1016\/j.jocn.2021.09.035_b0040","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.jocn.2021.09.035_b0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"\u201cLeukodystrophy-like\u201d phenotype in children with myelin oligodendrocyte glycoprotein antibodyassociated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jocn.2021.09.035_b0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between paediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2021.09.035_b0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.msard.2018.12.001","article-title":"Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination","volume":"28","author":"Zhou","year":"2019","journal-title":"Multiple Sclerosis Related Disorders"},{"issue":"10","key":"10.1016\/j.jocn.2021.09.035_b0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Paediatric Multiple Sclerosis Study Group criteria for paediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Multiple Sclerosis J"},{"issue":"2","key":"10.1016\/j.jocn.2021.09.035_b0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.09.035_b0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","article-title":"E.U. paediatric MOG consortium consensus: Part 1 e Classification ofclinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatric Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2021.09.035_b0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis Optica Study Group. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2021.09.035_b0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3174\/ajnr.A3382","article-title":"Development of a standardized MRI scoring tool for CNS demyelination in children","volume":"34","author":"Verhey","year":"2013","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.jocn.2021.09.035_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.593287","article-title":"Clinical and neuroimaging characteristics of paediatric acute disseminating encephalomyelitis with and without antibodies to myelin oligodendrocyte glycoprotein","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2021.09.035_b0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Multiple Sclerosis J"},{"issue":"4","key":"10.1016\/j.jocn.2021.09.035_b0095","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2021.09.035_b0100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.jocn.2021.09.035_b0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","article-title":"Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China","volume":"103","author":"Song","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jocn.2021.09.035_b0110","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.jocn.2021.09.035_b0115","doi-asserted-by":"crossref","unstructured":"Cobo-Calvo \u00c1, Ruiz A, D'Indy H, Poulat AL, Carneiro M, Philippe N, et al. (2017). MOG antibody-related disorders: common features and uncommon presentations. J Neurol 2017; 264(9): 1945-1955.","DOI":"10.1007\/s00415-017-8583-z"},{"key":"10.1016\/j.jocn.2021.09.035_b0120","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2021.09.035_b0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.jocn.2021.09.035_b0130","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","volume":"266","author":"Cobo-Calvo","year":"2019","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2021.09.035_b0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.09.035_b0140","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","article-title":"MRI of the first event in paediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein","volume":"265","author":"Baumann","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2021.09.035_b0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-abs-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2021.09.035_b0150","first-page":"e163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jocn.2021.09.035_b0155","first-page":"e40","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jocn.2021.09.035_b0160","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Multiple Sclerosis J"},{"issue":"5","key":"10.1016\/j.jocn.2021.09.035_b0165","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"NOMADMUS study group. The long-term outcome of MOGAD: An observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.jocn.2021.09.035_b0170","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821004914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821004914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:27:43Z","timestamp":1760822863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821004914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"alternative-id":["S0967586821004914"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.09.035","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics, disease course, and outcomes of paediatric patients with myelin oligodendrocyte glycoprotein-Ab associated disease: A retrospective clinical study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}